Drug interactions
Lutetium lu 177-dota-tate + Octreotide
Severity: Moderate
Lutetium lu 177-dota-tate and Octreotide: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Octreotide competes with Lu 177 dotatate for somatostatin receptor binding and may reduce tumor uptake and therapeutic efficacy. Labeling therefore requires timing separation around each radioligand dose.
What this interaction means in plain words
Lutetium lu 177-dota-tate and Octreotide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Competitive somatostatin receptor binding reduces radioligand uptake in tumor tissue.
What to do
Stop long-acting octreotide at least 4 weeks before each Lu 177 dotatate dose and short-acting octreotide at least 24 hours before. Resume octreotide as recommended after treatment, and use short-acting octreotide for symptom control between doses.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lutetium lu 177-dota-tate and Octreotide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Octreotide
Frequently asked questions
Can I take Lutetium lu 177-dota-tate with Octreotide?
MediHelp rates the interaction as moderate. Lutetium lu 177-dota-tate and Octreotide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Octreotide competes with Lu 177 dotatate for somatostatin receptor binding and may reduce tumor uptake and therapeutic efficacy. Labeling therefore requires timing separation around each radioligand dose.
How serious is the interaction between Lutetium lu 177-dota-tate and Octreotide?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Stop long-acting octreotide at least 4 weeks before each Lu 177 dotatate dose and short-acting octreotide at least 24 hours before. Resume octreotide as recommended after treatment, and use short-acting octreotide for symptom control between doses.
What other medicines interact with Octreotide?
MediHelp also lists interactions of Octreotide with, for example, Adagrasib, Amisulpride, Arsenic trioxide. The full list is on the Octreotide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
